Lukasz Matusiak

Prof. Dr. Lukasz Matusiak

orcid

Research Focus & Metrics

Representative Publications

View All Publications
30 January 2015 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
NDN. Desai
N. Desai
LEL. Emtestam
L. Emtestam
RHR.E. Hunger
R.E. Hunger
DID. Ioannides
D. Ioannides
GJG.B.E. Jemec
G.B.E. Jemec

21 July 2015 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
JBJ. Boer
J. Boer
ASA. Stratigos
A. Stratigos
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
IHI. Hamzavi
I. Hamzavi
GJG.B.E. Jemec
G.B.E. Jemec

1 May 2010 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
LMLukasz Matusiak
Lukasz Matusiak
ABA Bieniek
A Bieniek
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
Hidradenitis suppurativa is a recurrent, debilitating suppurative skin disease. The symptoms are much more than just physical, but studies o...

1 April 2010 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
LMLukasz Matusiak
Lukasz Matusiak
ABAndrzej Bieniek
Andrzej Bieniek
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski

1 April 2017 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
LMLukasz Matusiak
Lukasz Matusiak
JSJustyna Szczęch
Justyna Szczęch
ABAndrzej Bieniek
Andrzej Bieniek
DNDanuta Nowicka-Suszko
Danuta Nowicka-Suszko
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski

19 December 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
FBFalk G. Bechara
Falk G. Bechara
FBF. Benhadou
F. Benhadou
VBVincenzo Bettoli
Vincenzo Bettoli
ZMZ. Bukvić Mokos
Z. Bukvić Mokos
GJG. B. E. Jemec
G. B. E. Jemec
Introduction: This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.Objective: These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).Methods: The chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.Results: Since the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non‐inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non‐inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5‐day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate‐to‐severe HS. Various surgical procedures are available for the predominantly non‐inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.Conclusions: Suitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.